口服蛋氨酸酶治疗晚期前列腺癌患者的慢性治疗导致 PSA 水平迅速升高的长期稳定。
Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA Levels.
机构信息
AntiCancer, Inc, San Diego, CA, U.S.A.
出版信息
In Vivo. 2021 Jul-Aug;35(4):2171-2176. doi: 10.21873/invivo.12488.
Abstract
BACKGROUND/AIM: Advanced prostate cancer is a recalcitrant disease with very limited treatment options. Our laboratory discovered methionine addiction, presumably a characteristic of all cancer types, including prostate cancer, which can be targeted by methionine restriction (MR), through treatment with oral recombinant methioninase (o-rMETase).
PATIENTS AND METHODS
o-rMETase was produced by fermentation of recombinant E. coli containing the Pseudomonas putida methioninase gene, and purified by column chromatography. An advanced prostate cancer patient received o-rMETase as a supplement, 500 units per day, divided into two oral doses of 250 units each.
RESULTS
Before treatment, the patient had a rapid rise in PSA levels, from 39 to 56 ng/ml, within 6 weeks. At the 15 week of o-rMETase administration, the PSA levels stabilized at 62 ng/ml. No overt side effects were observed.
CONCLUSION
o-rMETase single treatment can be beneficial for advanced prostate cancer patients.
摘要
背景/目的：晚期前列腺癌是一种难治性疾病，治疗选择非常有限。我们的实验室通过用口服重组甲硫氨酸酶（o-rMETase）治疗发现，包括前列腺癌在内的所有癌症类型可能都存在蛋氨酸成瘾，这可以作为靶点，通过蛋氨酸限制（MR）来治疗。
患者和方法
o-rMETase 通过含有恶臭假单胞菌甲硫氨酸酶基因的重组大肠杆菌发酵生产，并通过柱层析进行纯化。一名晚期前列腺癌患者将 o-rMETase 作为补充剂服用，每天 500 单位，分为两次口服，每次 250 单位。
结果
在治疗前，患者的 PSA 水平在 6 周内从 39 迅速上升至 56ng/ml。在 o-rMETase 给药的第 15 周，PSA 水平稳定在 62ng/ml。未观察到明显的副作用。
结论
o-rMETase 单一治疗对晚期前列腺癌患者可能有益。
相似文献
1
Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA Levels.口服蛋氨酸酶治疗晚期前列腺癌患者的慢性治疗导致 PSA 水平迅速升高的长期稳定。
In Vivo. 2021 Jul-Aug;35(4):2171-2176. doi: 10.21873/invivo.12488.
2
Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.口服重组甲硫氨酸酶可使骨转移前列腺癌患者 PSA 降低 70%，晚期卵巢癌患者血循环中甲硫氨酸降低 50%。
Anticancer Res. 2020 May;40(5):2813-2819. doi: 10.21873/anticanres.14254.
3
Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.口服蛋氨酸酶降低晚期前列腺癌患者 PSA 水平并稳定其水平。
Anticancer Res. 2021 Apr;41(4):1921-1926. doi: 10.21873/anticanres.14958.
4
Development of Recombinant Methioninase for Cancer Treatment.用于癌症治疗的重组甲硫氨酸酶的研发。
Methods Mol Biol. 2019;1866:107-131. doi: 10.1007/978-1-4939-8796-2_10.
5
Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.甲硫氨酸限制联合口服重组甲硫氨酸酶和低甲硫氨酸饮食治疗直肠癌患者的长期稳定疾病。
Anticancer Res. 2022 Aug;42(8):3857-3861. doi: 10.21873/anticanres.15877.
6
Pilot Phase I Clinical Trial of Methioninase on High-Stage Cancer Patients: Rapid Depletion of Circulating Methionine.甲硫氨酸酶在晚期癌症患者中的I期临床试验：循环甲硫氨酸的快速消耗
Methods Mol Biol. 2019;1866:231-242. doi: 10.1007/978-1-4939-8796-2_17.
7
Oral Installation of Recombinant Methioninase-producing into the Microbiome Inhibits Colon-cancer Growth in a Syngeneic Mouse Model.口服重组蛋氨酸酶产生菌可抑制同基因小鼠模型结直肠癌的生长。
Cancer Genomics Proteomics. 2022 Nov-Dec;19(6):683-691. doi: 10.21873/cgp.20351.
8
Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer.口服重组蛋氨酸酶（rMETase）与5-氟尿嘧啶对低分化胃癌的协同作用
Biochem Biophys Res Commun. 2023 Feb 5;643:48-54. doi: 10.1016/j.bbrc.2022.12.062. Epub 2022 Dec 21.
9
Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients.重组蛋氨酸酶输注可降低晚期癌症患者血清蛋氨酸的生化指标，且毒性极小。
Anticancer Res. 1997 Sep-Oct;17(5B):3857-60.
10
Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment.人癌细胞的甲硫氨酸酶基因治疗与重组甲硫氨酸酶治疗具有协同作用。
Cancer Res. 2000 May 15;60(10):2696-702.
引用本文的文献
1
Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential.癌症中的甲硫氨酸依赖性与限制：探索致病功能和治疗潜力
Pharmaceuticals (Basel). 2025 Apr 28;18(5):640. doi: 10.3390/ph18050640.
2
HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine Restriction.获得性曲贝替定耐药的HT1080纤维肉瘤：恶性程度增加但对蛋氨酸限制持续敏感。
In Vivo. 2025 Mar-Apr;39(2):683-690. doi: 10.21873/invivo.13872.
3
Engineered Methioninase-expressing Tumor-targeting A1-R Inhibits Syngeneic-Cancer Mouse Models by Depleting Tumor Methionine.工程化表达甲硫氨酸酶的肿瘤靶向A1-R通过消耗肿瘤甲硫氨酸抑制同基因癌症小鼠模型。
Cancer Genomics Proteomics. 2025 Mar-Apr;22(2):247-257. doi: 10.21873/cgp.20499.
4
Targeting Methionine Addiction of Osteosarcoma with Methionine Restriction to Overcome Drug Resistance: A New Paradigm for a Recalcitrant Disease.通过限制甲硫氨酸靶向骨肉瘤的甲硫氨酸成瘾以克服耐药性：一种针对难治性疾病的新范式
Cancers (Basel). 2025 Feb 3;17(3):506. doi: 10.3390/cancers17030506.
5
Prostate Cancer Patient With Lymph-node Metastasis Treated Only With Methionine Restriction Has Stable Disease for Two Years Demonstrated With PET/CT and PSMA-PET Scanning and PSA Testing.仅接受蛋氨酸限制治疗的前列腺癌伴淋巴结转移患者，经PET/CT、PSMA-PET扫描及PSA检测显示，疾病稳定两年。
Cancer Diagn Progn. 2025 Jan 3;5(1):27-31. doi: 10.21873/cdp.10408. eCollection 2025 Jan-Feb.
6
Cribriform Pattern Is a Predictive Factor of PSA Recurrence in Patients Receiving Radiotherapy After Prostatectomy.筛状模式是前列腺切除术后接受放疗患者前列腺特异性抗原复发的预测因素。
Cancer Diagn Progn. 2024 Nov 3;4(6):715-721. doi: 10.21873/cdp.10386. eCollection 2024 Nov-Dec.
7
The Combination of Methionine Restriction and Docetaxel Synergistically Arrests Androgen-independent Prostate Cancer But Not Normal Cells.蛋氨酸限制与多西他赛联合使用可协同抑制去势抵抗性前列腺癌，但对正常细胞无此作用。
Cancer Diagn Progn. 2024 Jul 3;4(4):402-407. doi: 10.21873/cdp.10339. eCollection 2024 Jul-Aug.
8
Expression of PD-L1 Is Increased by Methionine Restriction Using Recombinant Methioninase in Human Colorectal Cancer Cells.蛋氨酸限制使用重组蛋氨酸酶增加人结直肠癌细胞中 PD-L1 的表达。
Cancer Genomics Proteomics. 2024 Jul-Aug;21(4):395-398. doi: 10.21873/cgp.20457.
9
Efficacy of Recombinant Methioninase on Late-stage Patient Cancer in the Histoculture Drug Response Assay (HDRA) as a Potential Functional Biomarker of Sensitivity to Methionine-restriction Therapy in the Clinic.重组蛋氨酸酶在组织培养药物反应测定（HDRA）中对晚期癌症患者的疗效，作为临床上对蛋氨酸限制疗法敏感性的潜在功能生物标志物。
Cancer Diagn Progn. 2024 May 3;4(3):239-243. doi: 10.21873/cdp.10314. eCollection 2024 May-Jun.
10
Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.替莫唑胺联合放疗联合口服重组甲硫氨酸酶和低甲硫氨酸饮食治疗高级别胶质瘤的青少年女性患者的广泛退缩和长期稳定疾病。
In Vivo. 2024 May-Jun;38(3):1459-1464. doi: 10.21873/invivo.13591.
本文引用的文献
1
Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.口服蛋氨酸酶降低晚期前列腺癌患者 PSA 水平并稳定其水平。
Anticancer Res. 2021 Apr;41(4):1921-1926. doi: 10.21873/anticanres.14958.
2
Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.口服重组蛋氨酸酶在临床相关的患者源性原位异种移植（PDOX）小鼠模型中，可将骨肉瘤从多西他赛耐药转变为敏感。
Anticancer Res. 2021 Apr;41(4):1745-1751. doi: 10.21873/anticanres.14939.
3
Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.口服重组蛋氨酸酶联合紫杉醇在患者来源的原位异种移植（PDOX）裸鼠模型中阻止难治性卵巢透明细胞癌的生长。
Cancer Chemother Pharmacol. 2021 Jul;88(1):61-67. doi: 10.1007/s00280-021-04261-x. Epub 2021 Mar 25.
4
Lipid remodeling in response to methionine stress in MDA-MBA-468 triple-negative breast cancer cells.丙氨酰-苏氨酰-天门冬酰-赖氨酰-脯氨酸对 MDA-MBA-468 三阴性乳腺癌细胞迁移和侵袭的影响及机制研究
J Lipid Res. 2021;62:100056. doi: 10.1016/j.jlr.2021.100056. Epub 2021 Feb 26.
5
Sensing and Signaling of Methionine Metabolism.甲硫氨酸代谢的感知与信号传导
Metabolites. 2021 Jan 31;11(2):83. doi: 10.3390/metabo11020083.
6
Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model.三甲基封锁与重组甲硫氨酸酶、环亮氨酸和阿扎胞苷联合阻断胰腺癌细胞来源的原位异种移植模型。
Pancreas. 2021 Jan 1;50(1):93-98. doi: 10.1097/MPA.0000000000001709.
7
Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells.甲硫氨酸限制下 H3K4me3 和 H3K9me3 的组蛋白甲基化状态在甲硫氨酸成瘾性癌细胞中不稳定，但在正常细胞中稳定。
Biochem Biophys Res Commun. 2020 Dec 17;533(4):1034-1038. doi: 10.1016/j.bbrc.2020.09.108. Epub 2020 Oct 3.
8
Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity.酶介导的血清 l-Met 耗竭通过多种机制阻断前列腺癌生长，而无全身毒性的证据。
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):13000-13011. doi: 10.1073/pnas.1917362117. Epub 2020 May 20.
9
Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.口服重组甲硫氨酸酶可使骨转移前列腺癌患者 PSA 降低 70%，晚期卵巢癌患者血循环中甲硫氨酸降低 50%。
Anticancer Res. 2020 May;40(5):2813-2819. doi: 10.21873/anticanres.14254.
10
Methionine Dependence of Cancer.癌症的蛋氨酸依赖性。
Biomolecules. 2020 Apr 8;10(4):568. doi: 10.3390/biom10040568.
Zotero 插件